Public Health & Policy
FDA Panel: Keep ECT Devices as High Risk
GAITHERSBURG, Md. -- The FDA should continue to regulate electroconvulsive therapy (ECT) machines as high-risk devices for treating depression and most other conditions for which ECT is typically used, members of the agency's Neurological Devices Advisory Committee agreed.
Jan 28, 2011
FDA Panel Rejects Cystic Fibrosis Drug
SILVER SPRING, Md. -- An FDA advisory committee has voted against approval of liprotamase (Sollpura), a pancreatic enzyme product for cystic fibrosis and other diseases that cause pancreatic insufficiency, saying there is not enough evidence that the drug works better than agents already on the market.
Jan 12, 2011
Novartis Settles Civil and Criminal Cases for $422.5 Million
Novartis will pay a $185 million fine for promoting off-label uses of the antiepilepsy drug oxcarbazepine (Trileptal) and another $237.5 million in civil penalties to settle a suit involving Trileptal and five other drugs, the Department of Justice announced.
Oct 01, 2010
FDA Advisers Turn Down New RSV Drug
WASHINGTON -- An FDA advisory committee recommended Wednesday that the agency not approve the investigational drug motavizumab to treat respiratory infections, deciding that it didn't offer any advantages over the drug already on the market, and that it may be more dangerous.
Jun 03, 2010
Contaminated Pepper Leads to Meat and Seasoning Recall
WASHINGTON -- Wholesome Spice of Brooklyn, N.Y. spice company is recalling 25-pound boxes of commercial-grade crushed red pepper as the CDC and FDA investigate an outbreak of Salmonella Montevideo that infected consumers of Italian-style meats produced by a Rhode Island firm.
Mar 01, 2010
Sildenafil Trial Halted in Patients with Sickle Cell Disease
LITTLE FALLS, N.J. -- The National Heart, Lung, and Blood Institute has halted a trial of sildenafil (Revatio) in sickle cell patients with pulmonary hypertension because of increased hospitalizations for sickle cell crises, or severe pain, the agency said.
Jul 29, 2009
Is Cash-Only Medicine the Next Big Thing?
As increasing numbers of physicians work longer and harder to maintain income levels in the face of declining third-party reimbursements, some have opted out -- they're running cash-only practices, and respondents to a Ƶ online spotcheck think more doctors will join them.
Mar 19, 2009